Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JC Medical developed the J-Valve™ system, a next-generation transcatheter aortic valve replacement (TAVR) technology targeting patients with aortic regurgitation and stenosis. The transapical version received regulatory approval and commercial launch in China. The transfemoral version has completed early feasibility studies in North America and China, with pivotal trials initiated following FDA Breakthrough Device designation. Clinical results have shown promise for treating severe aortic regurgitation, addressing an unmet need not well served by existing TAVR devices.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JC Medical.